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ABSTRACT 
Recurrent acute pancreatitis and chronic pancreatitis are labeled as idiopathic when no 
identifiable factors are found. The identifications of genetic mutations associated with 
pancreatitis have provided opportunities for identifying patients at risk for idiopathic 
pancreatitis.  
Aim:  
To study of clinical profile and prevalence of SPINK 1 mutation in idiopathic 
recurrent acute and chronic pancreatitis. 
Design:  
Prospective observational study of patients with idiopathic recurrent and chronic 
pancreatitis in a tertiary care hospital from November 2010 to 31st December 2011.  
Results: 
Fifty patients were included out which 17 patients were idiopathic recurrent acute 
pancreatitis and 33 were chronic. Out of 17 patients with RAP mean age was 22.29 ± 9.7 
years, duration of illness was 28.23 ± 10.34 months, 82% were male, 94% had BMI > 18.5 
kg/ m2  41.17% had SPINK1 mutation. Out of 33 patients with chronic pancreatitis mean age 
was 31.75 ± 13.07 year, duration of illness was 31.33 ± 19.89 months, mean  fasting sugar 
was 112.57 mg/dl, 67% were male, 93.94% had pain 87.8% had ductal dilatation on CT, 
36.36% were SPINK 1 positive.  
 
 
Conclusion:
SPINK1 mutation patients have more frequent episodes of pancreatitis and
parenchymal calcification on CT. The clinical profile of idiopathic chronic pancreatitis is
different from what has been reported in the past.
Key words:
Idiopathic Recurrent Acute Pancreatitis; Chronic Pancreatitis SPINK1 mutation
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INTRODUCTION 
 
  
Recurrent pancreatitis is defined as two or more attacks of pancreatitis and 
chronic pancreatitis is defined as a continuing inflammatory disease of the pancreas 
characterized by irreversible morphological changes and typically causing pain and 
permanent loss of function1,2. Many studies have been conducted on acute and chronic 
pancreatitis, but only few have focused on idiopathic chronic and recurrent acute 
pancreatitis.  
In clinical practice evaluation fails to detect the cause of pancreatitis in 10 – 
30% of the patients, and these patients are labeled as idiopathic chronic and recurrent 
acute (RAP) pancreatitis.  Evaluation is important in such patients since more than 
50% of   patients with RAP experience recurrent episodes that can lead to chronic 
pancreatitis3. 
Very few studies have been conducted on idiopathic recurrent acute 
pancreatitis. RAP can be due to biliary disease, alcohol, trauma, hypercalcemia, 
hyperlipedemia, or anatomical variations2. In clinical practice upto 30% do not have 
identificable factors and are labeled as idiopathic recurrent pancreatitis. 
Idiopathic chronic pancreatitis was early thought to be seen only in certain 
parts of India. During the last few years, many cases of idiopathic chronic pancreatitis 
have been reported from western world and almost all states in our country.  
Mutations in cationic trypsinogen gene (PRSS1), SPINK1 gene, cystic fibrosis 
transmembrane conductance regular gene (CFTR) and Cathepsin B gene have been 
studied in acute recurrent and chronic pancreatitis4-7.  
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Genetic mutations may be the cause of pancreatitis in patients whom etiology 
is not found. Idiopathic pancreatitis represents a complex disease process resulting 
from an interaction of genetic mutations and environmental factors. Recent research 
have shown complex interactions    like gene –gene, gene – environment in the 
pathogenesis of pancreatitis8.  A systematic study on clinical profile and prevalence of 
SPINK 1 mutation was studied in patients with idiopathic recurrent acute pancreatitis 
and idiopathic chronic pancreatitis. 
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AIMS AND OBJECTIVES 
 
To study the demographic and clinical profile of idiopathic recurrent acute 
pancreatitis and idiopathic chronic pancreatitis. 
To assess the prevalence of genetic mutation (SPINK 1) in idiopathic recurrent 
acute pancreatitis and chronic pancreatitis. 
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REVIEW OF LITERATURE 
 
Definition: 
 
Acute Pancreatitis:  is defined as a acute inflammatory disease of the pancreas 
presenting with abdominal pain and usually associated with elevated pancreatic 
enzymes in blood or urine9. 
Recurrent Acute Pancreatitis: is defined as two or more attacks of pancreatitis 
associated with at least twice normal serum amylase levels9. 
Chronic Pancreatitis: is defined as a continuing inflammatory disease of the 
pancreas characterized by irreversible morphologic changes that typically causes pain 
and or permanent loss of exocrine and or endocrine function. Pain is the predominant 
feature and is associated with pancreatic calcification, diabetes and steatorrhoea10. 
The newer imaging techniques like endoscopic ultrasonography (EUS), endoscopic 
retrograde pancreatography (ERCP), Magnetic resonance imaging changes are useful 
in detecting early changes in ducts and parenchyma. The identifications of genetic 
mutation associated with chronic pancreatitis like SPINK 1, CFTR, PRSS, have 
provided opportunities for identifying patients at risk for idiopathic pancreatitis11-13. 
This review of literature will focus on epidemiology, classification of chronic 
pancreatitis, etiopathogenesis and genetic developments in idiopathic recurrent and 
chronic pancreatitis. 
Incidence 
The study from China by Wang et al14 showed that 10.6% of their acute 
pancreatitis had recurrent episodes. The data from Europe by Gullo et al showed that 
out of the 1068 of acute pancreatitis, 288 (27%) had recurrence15.  
 The incidence of chronic pancreatitis appears to be around 3 – 10 patients 
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100000 population. The prevalence is now estimated to be around 13 per 10000016 
people. Idiopathic chronic pancreatitis is prevalent both in Western countries and 
India17. Recent study shows that chronic pancreatitis previously classified as tropical 
pancreatitis represents idiopathic chronic pancreatitis in India. The true incidence and 
prevalence of chronic pancreatitis in India are not known18.  This is because studies 
related to idiopathic pancreatitis have been difficult to do because of insidious onset, 
difficulty in diagnosis, and the fact that the disease presents often as acute or recurrent 
pancreatitis without any definite evidence of chronic pancreatitis19.  
 
Etiology and risk factors20-30 
The recurrent acute pancreatitis is called as idiopathic when no definite cause 
is found. The following are the few causes for recurrent acute pancreatitis.  
1. Gall stones 
2. Biliary sludge and Microlithiasis 
3. Alcohol 
4. Sphincter Oddi Dysfunctio 
5. Pancreas Divisum 
6. Drugs 
7. Hypertriglyceridemia 
8. Hypercalcemia 
9. Infection 
10. Biliary Ascariasis 
11. Trauma 
12. Vascular Diseases 
13. Tumours 
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14. Choledochocele 
15. Annular Pancreas 
16. Genetic Mutations 
Chronic Pancreatitis: 
 The exact etiology is partially known. Ethanol is considered as the commonest 
cause accounting for more than 50% of case along with other factors like hereditary, 
environmental anatomical variation, metabolic, genetics. Many classification systems 
have been proposed for chronic pancreatitis. These classification include  
(i) The Marseille classification (1963) and revised Marseille classification 
in 198431-32. 
(ii) The Marseille-Rome classification of 198833. 
(iii) The Cambridge classification of 198434. 
(iv) The Japan Pancreas Society classification for CP 35. 
(v) TIGAR -O classification36.   
 
TIGAR – 0 classification systems was proposed by Etemad and Whitcomb in 
2001 and is based on primarily on the etiology of chronic pancreatitis and takes into 
account of newer developments such as genetic mutations. 
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TIGAR -O Classification System for Chronic Pancreatitis 
Toxic Metabolic 
· Alcoholic 
· Tobacco Smoking 
· Hypercalcemia 
· Hyperlipemia 
· Chronic Renal Failure 
Idiopathic 
· Early onset 
· Late onset 
· Tropical  
Genetic 
· Autosomal dominant: cationic trypsinogen gene mutation 
· Autosomal recessive / modifiers genes: CFTR mutations, SPINK1 
Mutations 
Autoimmune 
· Isolated autoimmune CP 
· Associated with other autoimmune diseases (Sjogren syndrome- associated 
CP 
Recurrent and severe acute pancreatitis 
· Post - necrotic (severe acute pancreatitis) 
· Recurrent acute pancreatitis 
· Vascular disease / ischemic 
· Radiation injury 
8 
 
Obstructive 
· Pancreas divisum 
· Sphincter of Oddi disorder (controversial) 
· Duct obstruction (e.g) tumour 
· Periampullary duodenal wall cysts 
· Post –traumic  
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PATHOGENESIS 
 
Trypsin and Pancreatitis: 
Trypsin is a major pancreatic serine protease with two protein domains 
connected by a single side chain. Trypsinogen becomes trypsin with cleavage of a 
short chain exposed peptide chain called trypsinogen activation peptide by the action 
of enterokinase or by a second trypsin molecule. The trypsin contains a calcium 
binding pocket near the side chain connecting the globular domains. Enzymatic 
cleavage of the side chain by the second trypsin leads to destruction of the first trypsin 
molecule (autolysis). If the concentration of soluble calcium rises, calcium enters the 
binding pocket and limits exposure to enzymatic attack by another trypsin and 
prevents trypsin from autolysis37,38. 
Trypsin is susceptible to rapid autolysis within the acinar cell where calcium 
levels are low, protected from autolysis after active secretion into the pancreatic duct 
and duodenum where calcium levels are high, and then undergoes autolysis in the 
distal small intestine after calcium is absorbed in the distal duodenum and jejunum. 
Protective mechanisms against acute pancreatitis 
Intracellular protective mechanism include synthesis of trypsin as an inactive 
zymogen (trypsinogen), zymogen compartmentalization and packaging, synthesis of a 
specific trypsin inhibitor (PSTI or SPINK1), control of intra-acinar cell calcium levels 
to facilitate autolysis, and lysosome dependent pathways of zymogen / activated 
digestive enzyme eliminations39.  
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Once the zymogens are secreted into a calcium rich juice (eliminates the 
autolysis protective mechanism) the pancreas is dependent on SPINK1 (inhibit 
prematurely activated trypsinogen) and rapid flushing of the pancreatic duct by fluid 
from the duct cells to protect against pancreatitis. Disruption of any of these 
protective mechanisms increase susceptibility to acute pancreatitis and predisposes of 
chronic pancreatitis. The combined effect of environment and genetic factors in 
increasing the risk of recurrent acute and chronic pancreatitis39.  
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SPINK 1 Defense   
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Progression from pre-acute pancreatitis to chronic pancreatitis40. 
Pre-acute pancreatitis   
 
 
 
Acute Pancreatitis   
   
 
 
 
Mild acute pancreatitis           Severe acute pancreatitis 
 
Post acute Pancreatitis   
         
    
 
Chronic Inflammation / scarring 
 
Chronic Pancreatitis 
 
 
 
Risk factors 
- Genetic, alcohol 
- Metabolic factors 
Sentineal acute pancreatitis event – SAPE 
 
- Proinflammatory phase 
- Antiinflammatory phase 
 
Progression 
Recurrent acute pancreatitis      Chronic stressors 
- SPINK1         -     Alcohol, smoking 
- CFTR 
- PRSS1 
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RECENT CONCEPTS 
 Two important concepts have emerged as being important in the pathogenesis 
of CP including the so-called TCP. These include oxidative stress and genetic 
mutations.  
Oxidative Stress 
 Oxidative stress (OS) has been implicated recently in the pathophysiology of 
CP41-42. Xenobiotics are detoxified in the body through phase I and phase II pathways 
chiefly in the liver43. Increased exposure to alcohol, nicotine, petrochemical fumes 
may overwhelm the capacity of phase I and phase II detoxification pathways and 
result in oxidative stress. OS will damage these cell either directly by cell membrane 
destruction, depleting the cells of antioxidants or free radical mediated injury44-46.  
Genetic Mutation: 
The role of genetic mutations in CP has been studied for more than 30 years. 
Initial studies were directed toward the association of HLA genes with pancreatitis. In 
1950s, Comfort et al47 described Heridatary Pancreatitis as a highly penetrant, 
autosomal dominant condition. In 1998, studies showed an increased incidence of 
CFTR gene mutations in patients who had idiopathic CP48,49. In a landmark study, 
Whitcomb et.all50. reported arginine to histidine substitution at residue 117 
(subsequently renamed as R122h) in the cationic trypsinogen gene on the long arm of 
chromosome 7 (7q35) in hereditary pancreatitis. Witt and colleagues said that 
mutations in the SPINK 1 gene were associated with CP51. The discovery of 
heterozygotes  individuals with mutations in multiple genes and the resultant additive 
effect on disease underscores the complex nature of genotype and phenotype 
expression in CP 
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Cause of chronic pancreatitis and recognized associated genetic 
mutations 
Cause Genetic mutation 
(may have 1 or more) 
Alcoholic SPINK 1 
CFTR 
Tropical 
Hereditary 
SPINK 1 
PRSS 1 
SPINK 1 
CFTR 
Idiopathic SPINK 1 
CFTR 
 
Genetic Predisposition 
A genetic predisposition to chronic pancreatitis to among some families was 
recognised by Comfort et. al52. By genetic analysis it was discovered that mutation 
like (N291 and R122H) in the cationic trypsynogen (PRSSI) were associated with CP. 
Mutation in SPINK 1 have been associated with ICP and TCP. These discoveries not 
only provide insights into the molecular mechanism but present the possibility of 
powerful diagnostic tools. There are severe reasons why molecular and genetic 
analysis will become important in future. 
1. Mutation will provide information on risk of developing pancreatitis. 
2. Mutation detection will assist in early diagnosis  
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3. Mutation identified will provide rationale classification.  
4. Molecular classification will help in knowing disease progression and 
prognosis.  
5. Specific mutation will help in  gene environmental interaction 
6. Mutation may help in developing new therapeutic intervention 
7. Important for patients who are seeking answers for why they have pancreatitis  
 
Serine Protease inhibitor Kazal Type (1 (SPINK 1)  
The SPINK1 is also known as pancreatic secretory Trypsin inhibitors located 
on chromosome 5. It is a 56 amino acid peptide that inhibits Trypsin by Physically 
blocking the active site53,54. SPINK1 is synthesised by pancreatic acinar cells. It 
provides the first line defense against premature Trypsinogen activation within 
pancreas, because it is capable of inhibiting about 20% of Trypsin activity by 
competitively blocking the active site of Trypsin. In 2000, the role of SPINK 1 
mutation in chronic pancreatitis emerged. The most frequent mutation in (SPINK1) 
gene exon 3 results in asparagine to serine aminoacid change (N34 S) which leads to 
decreased trypsin inhibitory capacity. SPINK 1 (N34S), mutation are relatively 
common seen in 2% of general population. SPINK 1 mutation in patients with 
idiopathic chronic pancreatitis is markedly increased Proving that they are associated 
with chronic pancreatitis.Witt and colleagues were first to study an association 
between SPINK and idiopathic Chronic pancreatitis chronic pancreatitis have 
occurred with homozygous, heterozygous genotypes. SPINK 1 mutation appears to 
act on disease modifer lowering the threshold for initiating pancreatitis and hence 
important role in recurrent acute pancreatitis and chronic pancreatitis55,56. The severity 
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of pancreatitis appears to be similar between homozygous, heterozygous or compound 
heterozygous genotypes suggesting that genetics is complex.  
 
Cationic Trypsinogen mutations 
The Cationic Trypsinogen mutation is seen in many cases of hereditary 
pancreatitis. The R122H and N29I mutations interfere with autolysis and cause 
premature trypsinogen activation5,39,57. Nearly 60 – 80% who inherits the mutation 
will develop pancreatitis. Nearly 50% of individuals with acute pancreatitis will 
develop chronic pancreatitis.  
 
CFTR39 
CFTR gene is located on the long arm of chromosome 7, when both alleles of 
CFTR gene are involved; cystic fibrosis with pancreatic insufficiency can develop. 
Compound heterozygosity of CFTR gene with one severely affected and one 
moderately affected allele has shown to be cause of recurrent pancreatitis. CFTR may 
be part of a complex process in which heterozygous CFTR and heterozygous SPINK 
1 mutations cause recurrent acute pancreatitis.  
 
Cathepsin B: (CTSB) 
Cathepsin B is a lysosomal cysteine proteinase involved in the initial 
activation of Trypsinogen58. Recent study by Madhurkar et al showed CTSB mutation 
doubled the risk for Tropical Pancreatitis59. 
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Idiopathic chronic pancreatitis60 
Idiopathic chronic pancreatitis includes patients in whom no associated factors 
can be identified. The discovery of new genetic factors, environmental factors and 
metabolic factors will reclassify - and reduce the numbers of patients in this category. 
Idiopathic chronic pancreatitis has long been shrouded in mystery as far as its 
etiopathogenesis is concerned. Many different theories have been proposed like 
immune-mediated injury and environmental toxins however newer studies have 
discarded above hypothesis. Idiopathic CP that is prevalent in India is also known as 
tropical calcific pancreatitis by some authors61.  
Early and late onset 
The age of onset in idiopathic pancreatitis is bimodal as observed by Layer et 
al. In early onset calcification and exocrine and endocrine deficiency develops slowly 
than late onset. In late onset pain was absent in nearly 50% of patients. Pbtizone62 
indentified SPINK 1 mutation in about 25% of patients with idiopathic chronic 
pancreatitis. Patients with SPINK1 mutation developed pancreatitis before age of 20 
in many studies. 
Tropical Chronic Pancreatitis17 
Tropical chronic pancreatitis is referred to as type of idiopathic CP occurring 
in tropical countries. They can be subgrouped as Tropical calcific pancreatitis. TCP 
Characterised by multiple episodes of abdominal pain in childhood, extensive 
pancreatic calcification and pancreatic dysfunction but no diabetes at time of 
diagnosis. The other group is called as fibrocalculous pancreatitis diabetes (FCPP) in 
which diabetes mellitus is the first major complaint63. The etiology of tropical calcific 
pancreatitis is poorly understood. Many theories environmental factors, malnutrition, 
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 dietary Toxin like cyanogenic glycosides and micronutrient deficiency have been 
proposed. Recent reports from genetics studies have shown significant association 
between (SPINK1 and cationic trypsinogen mutation)  
 
CLINICAL FEATURES 
 
Recurrent acute Pancreatitis64 
 
All patients have recurrent attacks of upper abdominal pain at the onset. The 
pain is accompanied by nausea and vomiting in around 90% of patients. Patients can 
also present with severe pancreatitis which is associated with organ failure.  
Chronic Pancreatitis 
 The abdominal pain is the common presenting symptoms. The patient 
experience many attacks of severe pain in the middle or upper abdomen. The natural 
history of pain is highly variable and can present as intermittent or chronic pain. The 
other symptoms include diarrhea, weight loss, endocrine insufficiency (diabetes), 
jaundice or complications of acute episodes. The physical examination does not help 
to establish diagnosis however fullness, tenderness can be elicted. Patients with 
advanced disease show signs of malnutrition 
Approach to Determine etiology of recurrent Pancreatitis: 
 
 
Evaluation of a patient after the first attack of pancreatitis includes a careful 
history, lab studies (lipid profile, serum calcium, Anti nuclear anti body, Liver 
function tests) and USG abdomen65,66. Approximately 20% to 50% of patients with 
acute pancreatitis will have a recurrence. EUS / MRCP should be done to identify gall 
bladder sludge, small CBD stones, pancreas divisum, pancreatic tumors and early 
chronic pancreatitis. In clinical practice, ERCP is seldom done. For patients with  
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idiopathic acute pancreatitis, selective use of genetic testing may be appropriate. For 
the patient with RAP, especially in the setting of an appropriate family history, 
genetic testing for cationic trypsinogen gene (PRSS1), SPINK 1 gene can be done. 
The role of genetic testing for these mutations is less clear and controversial57.  
 
Chronic Pancreatitis: 
The diagnostic approach to chronic pancreatitis has evolved considerably in 
recent years. The investigations used can be summarized as below: 
· Imaging of pancreas and pancreatic ducts. 
· Tests for pancreatic exocrine insufficiency: to assess the degree of exocrine 
dysfunction (e.g.,fecal chymotrypsin) and sometimes to monitor 
replacement therapy(e.g.,fecal fat estimation).  
· Tests for pancreatic endocrine deficiency. 
 
Biochemical Blood Tests  
 Serum trypsin exists mainly as the cationic form of its precursor trypsinogen. 
In states of pancreatic insufficiency, the precursor gets converted to active trypsin. 
The active trypsin is mostly bound by protein inhibitors and become undetectable by 
catalytic assays69. The study by pezzilli70 et all has found it to be 28% sensitive but 
100% specific in identifying chronic pancreatitis. However, other studies have shown 
it to be only 50-60% sensitive in detecting chronic pancreatitis.  Serum lipase and 
amylase levels are elevated during acute pancreatitis but are of limited value to 
diagnose chronic pancreatitis. 
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IMAGING TESTS: 
Transabdominal Ultrasonography 
 Transabdominal ultrasonography can be used to visualize alterations of the 
pancreatic duct, pancreatic calcification or stones.  Abdominal ultrasound is highly 
sensitive in detecting severe chronic pancreatitis but the sensitive is much less in 
milder forms of the disease71.   
Computed Tomography (CT) Scan72 
 Computed tomography scan is one of the important diagnostic modalities in 
detection of chronic pancreatitis.  In chronic pancreatitis, a non-contrast-enhanced CT 
scan shows chronic pancreatitis. The contrast-enhanced pancreatic imaging produced 
by thin-multidetector row scanners can detect any abnormality in the size and shape of 
the gland, any parenchymal attenuation, any dilation or stones in the pancreatic duct 
and pancreatic pseudocysts. 
Magnetic Resonance Imaging (MRI)73 
Magnetic resonance imaging cannot detect extraductal pancreatic calcification 
as well as CT sacn can. Both T1and T2 weighed images may be used to detect severe 
forms of chronic pancreatitis, though the findings are less specific in the elderly 
patients. 
Endoscopic Retrograde Cholangiopancreatography(ERCP) 
ERCP can be used as a diagnostic as well as therapeutic tool in patients with 
chronic pancreatitis. It can detect dilatation and stenosis of pancreatic ducts, 
pancreatic stones or cysts.   
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Endoscopic Ultrasonography (EUS)74 
Endoscopic ultrasound is the diagnostic modality of choice to evaluate patients 
with early or mild chronic pancreatitis. EUS helps enables the clinician to assess the 
pancreatic parenchyma as well as the pancreatic duct.  The ducts are studied for 
narrowing, dilation, irregularity, calculi, side-branch dilation and hyperechoic walls   
EUS is considered superior to ERCP or MRCP for detection of early or mild changes 
of chronic pancreatitis as well as small duct involvement.                  
GENETIC TESTING 
Genetic testing, though not a preferred diagnostic tool directly involved in 
detection of chronic pancreatitis, can be done in with suspected hereditary or 
idiopathic disease. The test is not routinely available and the screening test too 
expensive for routine usage. 
TREATMENT 
Recurrent Acute Pancreatitis 
Mild pancreatitis is treated with supportive care including pain control, 
intravenous fluids. Severe pancreatitis requires intensive care and monitoring and 
advanced fluid resuscitation. The role of antibiotics have be debatable.  Nutritional 
support is required for severe pancreatitis with parenteral or enterally. 
Chronic Pancreatitis 
Management options for chronic pancreatitis include medical, endoscopic and 
surgical treatments. Patients with chronic pancreatitis seek medical attention because 
they suffer from abdominal pain, weight loss or diabetes.  
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Treatment of Pain75,76 
The pathophysiology of pain in chronic pancreatitis is incompletely 
understood. The proposed theories are ductal and mechanical mechanism, 
neuropathic, oxidative stress and central mechanism of pain. The management of pain 
in chronic pancreatitis is frustrating both for patients and clinicians.  The following 
tables summarize the management of chronic pancreatitis.  
 
Mechanisms of Pain in Chronic Pancreatitis and Management 
Options77 
Proposed mechanism of 
pain 
Management  options 
Duodenal Obstruction Surgical bypass or endoscopic stent 
Bile duct obstruction Endoscopic stent or surgery 
Pseudocyst Endoscopic, surgical or percutaneous drainage 
Pancreatic duct obstruction 
(stone or stricture) 
Endoscopic or surgical ductal decompression 
Tissue hypertension and 
ischemia 
Antioxidants, endoscopic and surgical ductal 
decompression 
Intra-pancreatic nerve injury Celiac  plexus block or neurolysis 
Visceral nerve sensitization Tricyclic antidepressants, SSRI, combined 
serotonin and norepinephrine re-uptake inhibitors 
Central nerve sensitization Tricyclic antidepressants, SSRI, combined 
serotonin and norepinephrine re-uptake inhibitors 
Elevations in cholecystokinin Non-enteric  coated pancreatic  enzymes 
 
23 
 
 
 
Options for Medical Management of Pain in Chronic Pancreatitis75,76 
Agent Dose 
Propoxyphene with acetaminophen 1-2 po q8h 
Tramadol (50 mg) 1-2 po q8h 
Antioxidants A combination of 500 – 1000 mg of Vit 
C, 250-300 IU of Vit E, 500 – 800 ug of 
selenium, 2 g of methionine, 9000 – 
10,000 IU of beta carotene per day in 
divided doses 
Tricyclic antidepressants Amitriptyline (start  at 25 mg qhs) 
Pancreatic enzymes Non enteric coated, protease content 
25,000 – 50,000 USP with each meal Co-
treatment with H2 blockers and PPI if 
needed to prevent degradation by gastric 
acid 
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MATERIALS AND METHODS 
Study Design 
Prospective analysis of patients with idiopathic recurrent acute and idiopathic 
chronic pancreatitis attending PSG Hospital, Coimbatore during the period 
Novermber 2010 to December 2011.  
Study centre 
The study was done in the Department of Gastroenterology PSG Institute of 
Medical Sciences and Research (PSG IMSR) in collaboration with the Centre for 
Molecular Medicine and Treatment (CMMT), PSG IMSR, Coimbatore. 
Ethical approval: 
The study protocol was approved by the Institute Human Ethics Committee 
(IHEC) prior to the start of the study. 
 
Subjects: 
Total of 50 patients were included in the study out of which 33 patients were 
idiopathic chronic pancreatitis and 17 patients were idiopathic recurrent acute 
pancreatitis.  
Inclusion Criteria 
 Criteria for Idiopathic recurrent pancreatitis: 
1. Two or more documented episodes of typical pancreatic type of abdominal 
pain 
2. Amylase or lipase greater than 3 times the upper limit of normal 
3. Features of acute pancreatitis on imaging studies (ultrasound / CT 
abdomen) 
4. No identifiable cause or risk factors  
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Diagnosis of Idiopathic chronic pancreatitis: 
The diagnosis of idiopathic chronic pancreatitis was made based on clinical 
setting and evidence of pancreatic duct dilatation irregularity and/ or pancreatic 
calcification on imaging studies without any identifiable cause or risk factors.  
 
Work up 
All patients underwent complete blood counts, biochemical investigations 
including liver function test, renal function, fasting blood sugar, serum calcium, lipid 
profile, serum amylase and lipase, antinuclear antibody, endocrine workup Ig4 levels 
viral serology and bile for microlithiasis after informed consent. The following 
imaging studies were done 
1. Transabdominal ultrasonography 
2. Contrast enhanced CT abdomen 
3. MRCP / EUS if indicated  
Complications of Chronic Pancreatitis like diabetes mellitus, steatorrhoea, bile 
duct obstruction, pseudocyst were diagnosed as per standard criteria either 
biochemically or imaging.   
Exclusion Criteria: 
1. Patients with identifiable cause and risk factors for chronic and recurrent 
pancreatitis.  
2. Malignancy 
3. Retroviral infection 
4. Psychiatry illness 
5. Hereditary and genetic diseases 
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Genetic analysis 
Steps involved in genotype analysis were 
• DNA extraction 
• PCR to amplify SPINK gene 
• RFLP using Pst I restriction enzyme 
• Poly Acrylamide Gel Electrophoresis (PAGE) of the digested  product 
 
DNA extraction was done according the standard protocol as follows 
• Blood sample 300μl + 1 volume of cell lysis buffer + 3 volume of sterile MilliQ 
water mixed up in 2 ml Eppendorf tubes which were then incubate on the ice 4°C 
for 10 minutes. 
• The samples centrifuged at 4° C for 20 minutes at 4000 rpm. 
• The supernatant discarded and again 150μl of same cell lysis buffer added in 
every sample and 480 μl of autoclaved H2O also added. 
• The sample then centrifuged at 4°C for 20 minutes at 4000 rpm. Then again the 
supernatant was discarded. 
• Then 720μl of nucleic acid lysis buffer, along with add 15μl of RNAse added to 
the eppendorf tube. 
• The samples were vortex mixed and incubated for 10 -15 minutes at 37°C. 30μl of 
10% SDS and 30 μl of Proteinase K then added. 
• The sample was incubated in water bath or heat block at 55°C for 2-3 hours. 
• Equal volume of phenol: chloroform (1:1) added and centrifuged at 15800rpm for 
5 minutes. 
• The supernatant of the samples (aqueous layer) transferred to the new tube. 
27 
 
• Equal volume of chloroform again added and centrifuged at 13000rpm for 
5minutes. 
• The supernatant then transferred to new tube and add 0.1x volume of 3M of 
sodium acetate (pH 6.0) and 2x volume of 100% ethanol and mixed well, 
centrifuged at 13000rpm for 10 minutes. 
• Then DNA was completely washed with 70 % ethanol and centrifuged again 
at13000rpm for 10 minutes. Supernatant ethanol discarded and the tubes dried. 
The DNA pellet was re-suspended in sterile water or TE buffer. DNA sample 
stored at -20°C. Quantification of the extracted genomic DNA was done using 
Nanodrop quantification after 0.8% agarose gel electrophoresis. 
 
PCR amplification of SPINK gene 
1. Primers 
Forward primer SPINKF:TTCTGTTTAATTCCATTTTTAGGCCAAATGCTGCA 
Reverse primer SPINKR: GGCTTTTATCATACAAGTGACTTCT 
2. DNTPs (Himedia) 
3. Taq DNA polymerase (colourless Taq Genei) 
4. Taq Buffer A (Genei) 
5. DNA Sample Optimised concentration: 0.05μg 
6. Milliq water 
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Table 1: PCR Reaction Mix- Volume of reagents used 
 
S. NO COMPONENTS VOLUME FINAL CON 
 
1 Forward primers - 1 µM      1 µL 50 nM 
2 Reverse primers - 1 µM                       1 µL 50 nM 
3 Buffer A                          2 µL 1.5mM Mgcl2 
 
4 DNTPs 0.8 µL 100µM  each 
DNTPS 
5 Taq enzyme                              0.2 µL 0.01 unit 
 
6 DNA sample (0.15μg) 
 
- 0.15μg/ 20µL 
7 Milli Q Water UPTO 20 µL  
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PCR reactions were performed on Eppendorf thermocycler. 
The mix was kept in cycler with following conditions. 
PCR PROGRAME 
1. Initial denaturation   -  94⁰C  for 10 min 
2. Denaturation   -  94⁰C  for 50 sec 
3. Annealing    -  57.7⁰C  for 50 sec             40 CYCLES 
4. Extension   -  72⁰C  for 1 min 
5. Final extension  -  72⁰C  for 5 min 
6. Then held at 4⁰C   
 At the end of reactions, PCR amplification was confirmed by electrophoresis 
on 2% agarose gel. 
2% Agarose gel electrophoresis  
1. To 30 ml of 1X TAE buffer, 600 mg of agarose was added and the contents 
were heated in 
2. a microwave until it formed a clear solution. 
3. To this 0.2μl of ethidium bromide was added and the solution was poured into 
a trough with 
4. a comb 
5. The solution was allowed to set for approximately 30 minutes. 
6. Once set, the comb and the tape around the trough are removed. 
7. The trough was then placed in an electrophoresis tank containing 1X TAE 
buffer. The 
8. trough should just immerse in the buffer. 
9. Loading dye was mixed with 100bp ladder in a sterile PCR tube. 
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10. 15 μ of each PCR DNA with 2μl of dye aliquotted separately in PCR tubes. 
11. The wells were loaded and electrodes were connected and run at 80V for 45 
minutes until 
12. the loading dye was seen for 3/4th of the gel. 
13. The trough was removed and gel viewed under UV illuminator for the 
presence of bands of product size 320bp 
 
Quantification of PCR DNA Product using Nanodrop quantification. 
 Spectrophotometer was used to check the quality and quantity of the extracted 
DNA. The Principle here involves measuring optical density of the DNA sample at 
260 nm and 280 nm Wavelengths. The purines and pyrimidines in DNA absorb UV 
radiation at 260 nm and the aromatic aminoacids in proteins absorb UV radiation at 
280 nm. The ratio of optical density at 260 and 280 nm is an estimate of the DNA 
quality. The optimal range for DNA of high Quality is 1.8 to 2.0. The concentration of 
the DNA sample was also determined Spectrophotometrically. 
 
RFLP Enzyme Digestion 
Requirements  
1. PstI (Fermentas 10 units/ μL)  
2. 10 x Buffer O 
3. PCR product (optimized concentration 0.6 μg) 
4. 37⁰C incubator 
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 The PCR amplified product was digested with PstI restriction enzyme at 37⁰C 
overnight. The 320 base pair (bp) DNA fragment was split into 286 and 34bp DNA 
Fragments if A→G substitution of the SPINK gene is present. 
Table 2: Reaction Mix for RFLP 
S. NO COMPONENTS VOLUME 
1 Pst I Enzyme               1.0 μl 
2 10X Buffer                               2 μl 
3 PCR product Concentration 0.6 μg 
4 Milli Q Water  Upto 31.5 μl 
 
 Reaction mix was incubated overnight at 37⁰C 
· Restriction digestion product was inactivated by adding 1.3 μl of 0.5 M EDTA 
before gel Electrophoresis. 
Polyacrylamide Gel Electrophoresis 
 The DNA Fragments were separated using 12 % Polyacrylamide gel 
electrophoresis Polyacylamide gel prepared from the following reaction mix. 
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Table 3: Reagents to prepare 12% Polyacrylamide gel 
 
12% 5mL 10mL 15mL 20mL 25mL 30mL 40mL 50mL 
Water 1.75 3.4 5.15 6.8 8.55 10.1 13.6 16.9 
A:B (30:0.8) 2 4 6 8 10 12 14 20 
1.5M Tris pH 8.8 1.3 2.5 3.8 5 6.3 7.5 10 12.5 
10% APS 0.05 0.10 0.15 0.2 0.25 0.3 0.4 0.5 
TEMED 0.002 0.004 0.006 0.008 0.01 0.012 0.016 0.02 
 
· Polyacrylamide gel was run in Amersham electrophoresis system at 90 V for 
about 7 hours. 
· The gel was then stained with ethidium bromide 
· The stained gel was viewed in a Chemiluminescence gel documentation 
system to 
· Identify the DNA fragments 
 
Identification of Genotypes 
The genotypes were determined based on the expected product size. 
   A/A   Genotype   (Asn 34 Asn)       -   320bp 
   G/G   Genotype   (Ser 34 Ser)          -  286bp 
  A/G    Genotype   (Asn 34 Ser)        -  320,286 and 34 
 
Statistical Analysis 
 Data were collected and analysed and expressed as mean and standard 
deviation. The SPSS version 10.0 program was used for statistical analysis.   
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RESULTS 
Recurrent Acute Pancreatitis (RAP) 
 There was total of 17 patients and mean age of patient was 22.29± 9.70 years 
and the youngest being 14 years and the oldest 39 years with 14 patients below 30 
years of age. The duration of illness was 28.23±10.34 months and mean fasting 
glucose level was 91.64±15.94 mg /dl. The following graph represents age category  
  
 
 
 
Figure 1 
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Sex Distribution: 
 
 82% of patients were males and 18% were females suggesting male 
preponderance  
 
Figure 2 
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Number of Episodes: 
 
The number of episodes of recurrent acute pancreatitis in patients is shown in 
the Table 1. The majority of the patients had 3 episodes. Patients with spink positive 
had more number of episodes compared to wild type. All the SPINK positive patients 
had 4 and above episodes. 
 
 
 
 
Table 1 
 
 
 
 
 
 
 
 
Episodes No. of 
Patients 
No. of SPINK 
positive 
Upto 3 8 - 
3 -4 2 5 
4-5 - 1 
> 5 - 1 
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Body Mass Index 
 
Majority of patients had BMI >18.5 
 
Figure 3 
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SPINK Mutation  
 
Out of 17 patients with idiopathic recurrent pancreatitis 41.17% (7) were 
positive for mutation  
 
Spink Mutation No. of Patients 
Wild Type 10 
Hetrozygous 7 
 
Table 2 
 
Figure 4 
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Age category and BMI of SPINK mutant patients 
 
 
Figure 5 
 
Figure 6 
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IDIOPATHIC CHRONIC PANCREATITIS  
There were 33 patients included and mean age was 31.75±13.07 years with 
youngest being 9 yrs and oldest being 69yrs. The mean age of patients with SPINK 
positive was 31.96yrs. The mean duration of illness was 31.33±19.89 months and 
mean fasting  sugar level was 112.57mg /dl  
 
 
Figure 7 
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Gender Bifurcation 
 
67% of patients were males and 33% were females.  
 
 
 
Figure 8 
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Clinical Features   
Nearly 93.34%of patients had pain as their clinical symptoms. The following 
table shows various manifestations among 33 idiopathic chronic patients. 
 
 
 
 
 
 
 
 
Table 3 
 
Figure 9 
 
 
Clinical Features  
No. of Patients 
N = 33 
Pain 31     (93.94%) 
Weight Loss 8      (24.24%) 
Diabetes 11    (33.33%) 
Steatorhea 5      (15.15%) 
Bile Duct Structure 2     (6.06%) 
Pseudocyst 2     (6.06%) 
Jaundice 2     (6.06%) 
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Body mass index  
Nearly 78.78% of patients had no evidence of malnutrition as evidenced by 
BMI >18.5  
 
 
 
 
Figure 10 
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CT Findings  
 
 
73.75% (25) of patients had ductal dilation and around 87.87% (29) had 
parenchymal calcification. All the patients with SPINK positive had 100% 
parenchymal calcification. The following table represents CT findings among 33 
patients 
 
  CT Findings 
No. of Patients 
N=33 
Spink  positive 
N=12 
Ductal Dilation 25 10 
Parenchymal Calcification 29 12 
 Ductal Calculi  7 2 
Atrophy Pancreas  21 9 
 
Table 4 
 
 
 
 
Figure 11 
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SPINK Mutation  
 
36.36% of patients were having spink mutation. The following graph 
represents the number of patients with age category of spink mutation.   
 
Spink Mutation  No. of Patients 
Wild Type 21 
Hetrozygous  10 
Mutant 2 
 
Table 5 
 
 
 
 
 
Figure 12 
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Figure 13 
 
 
 
 
BMI in SPINK mutant patients 
 
 
BMI 
Spink Mutant 
Patients 
>18.5 11 
<18.5 1 
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DNA ISOLATION  SAMPLES 1-10
1     2     3     4      5     6     7      8      9    10   11    12   13
WELLS 2 -11 - GENOMIC DNA
DNA ISOLATION  SAMPLES 1-10
1     2     3     4      5     6     7      8      9    10   11    12   13
WELLS 2 -11 - GENOMIC DNA
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RFLP PCR  FOR SAMPLES 1-10
1      2      3      4       5      6       7      8      9     10     11    12     13
320 bp 320 bp215 bp
WELLS 1 -5 , 7-11 - PCR PRODUCT - 320bp
WELL    6                - REFERENCE PCR PRODUCT - 215bP
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1     2    3    4     5    6    7   8    9   10  11  12   13
320bp +286bp 286bp320bp
WELL  1 - UNCUT - 320 bp
WELLS 3,5,6,7,9,11 &12   - WILD TYPE - 320 bp
WELLS 4&10 - HETEROZYGOTE - 320bp+286bp
WELL 8 - MUTANT - 286bp                           
12 % PAGE FOR SAMPLES 1- 10
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DISCUSSION 
 
The current study is a prospective analysis of 17 patients diagnosed to have 
idiopathic recurrent acute pancreatitis and 33 patients of idiopathic chronic 
pancreatitis. Idiopathic chronic pancreatitis has been increasing in India and clinical 
profile is different compared to Tropical calcific pancreatitis. 
 
Recurrent Acute Pancreatitis (RAP) 
The mean age of patients in our study was 22.29 years. The mean age of 
patients in the studies done by Wang etal14 and Gullo15 et al were  41 and 43 years 
.The slightly older age of presentation in the above studies was  due to alcohol 
etiology .All our patients had recurrent episodes of more than two which was similar 
to the study by Garg78 et al . Our study had 17 patients out of which 7 (41.17%) were 
positive for SPINK mutation and all 7 patients had more no of recurrent episodes 
compared to wild type (no mutation).  The study by Whitcomb30 has shown that 
significant cases of idiopathic recurrent acute pancreatitis have genetic components 
like SPINK, CFTR. His genetic theory on pancreatitis says that carrying SPINK 
mutation leads to increased episodes of acute pancreatitis and which leads to chronic 
pancreatitis later .Giulia79 et al however did not find a statistically significant 
association with this mutation.  
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Idiopathic Chronic Pancreatitis (ICP)  
The mean age of ICP was in our study was 31.75 years. A study by 
Balakrishnan80 et al showed mean age of patients was 30 years. Data from Layer et 
al81 from United States should mean age of 19 yrs. Kandula et al82 showed idiopathic 
chronic pancreatitis occurred among children and adolescents. The mean age of 
patients from north India in a survey was 36.7 years and study from New Delhi 
showed majority of patients were younger83,84.  
Majority of the patients in our study were male (67%).  Data from prospective 
nationwide study from India showed male prepordance19. Study by Balakrishnan80 et 
al showed male to female ratio of 2:7:1. A study from Delhi and Lucknow showed 
majority of their patients with tropical pancreatitis were males.  
In our study mean duration of symptoms at the time of presentation was 31 
months. The study from Delhi reported mean duration of 48 months while Shallu 
midha et al showed in their study mean duration was 27 months85,86.  
Pain was the common presentation in our study which was similar to other 
studies by Layer et al81. Balakrishnan et al80. Shallu midha etal86 reported 97 % 
presented with pain which was similar to our data.   
Diabetes was reported in 33% of patients in our study which is diferrent from study 
conducted by Geeverghese87 and Tandon et al who in their study showed upto 90% of 
patients having diabetes. The study by Balakrishnan80 et al showed higher incidents  
of diabetes upto 70%. The study from lucknow reported diabetes in 26% of patients 
with idiopathic chronic pancreatitis .Midha et al86 also reported 27% patients having 
diabetes in chronic idiopathic pancreatitis  
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In our study sympotamatic steatorrhea was seen around 15%.while Midha et 
al86 reported frequency of 5% steatorrhea in their study and data from New Delhi also 
showed around 5% of patients with steatorrohea85. 
The present study showed 78% (26) of patients with BMI > 18.5 and 22% (9) 
with BMI < 18.5. This is in contrast to older studies from Kerela which showed high 
incidence malnutrition87,88. Midha et al86 and Narendranathan89- showed lack of 
association of malnutrition and Cassavsa consumption in their study. In 1988 study by 
Balakrishnan implicates malnutrition in pathogenesis of tropical calcific pancreatitis.  
The study from lucknow and delhi showed mean BMI of 19+3 kg/m and 20.2 
kg/m2 85. 
Ultrasound and CT findings included dilated pancreatic duct, calculi, atrophy. 
CT was more sensitive in identifying ductal dilatation and calcification. Study from 
all India institute of medical science showed usefulness of ultrasonographic   
evaluation of calcific pancreatitis85. Sensitivity of identyfing ductal dilatation and 
calcification by ultrasound is less than CT abdomen or MRI. In our study 87.87% had 
parenchymal calcification 75% had ductal dilation and only 21% had ductal calculi. 
The study from lucknow reported 57% of their patients with tropical pancreatitis had 
calcification. Khuroo et al90 reported 96 % of patients with tropical calcific pancreatis 
had pancreatic ductal calculi . All the 12 patients with SPINK mutation had 100% 
(12) parenchymal calcification and 75 % (9) atrophy of pancreas on CT.  
The aetiology of idiopathic pancreatitis is not well known. Recent studies have 
implicated SPINK 1 and CFTR gene in idiopathic chronic pancreatitis. Study by 
Bhatia et al56, Sundaresan et al91 have shown strong association of tropical calcific 
pancreatitis with SPINK 1  Our study showed 36.36% of patients with SPINK 
mutation .The  study of Bhatia et al showed SPINK 1 mutation  was found in 40% of 
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patients with tropical idiopathic chronic pancreatitis in India. In a study from 
Bangladesh Schneider et al92 showed there was difference in SPINK1 mutation 
between patients with tropical calcific pancreatitis having diabetes and - without. An 
Italian study by Macarena Gomez - showed association of SPINK 1 and CFTR gene 
mutation in idiopathic pancreatitis. In addition to SPINK1, CFTR gene mutations 
have been found in patients with CP than controls. The data from AIIMS showed 42% 
of patients had SPINK mutation and 9% CFTR mutation in patients with idiopathic 
chronic pancreatitis61. Studies from south India showed SPINK gene mutations were 
common in patients with idiopathic chronic pancreatitis .The important studies from 
Chen et al93, Witt et al13 showed significantly higher frequency of n34s mutation in 
spink gene in patients with idiopathic chronic pancreatitis  
Thus genetic mutations seen to play an important role in the pathogeness of 
idiopathic chronic pancreatitis. Recent study have shown role of chymotrypsin C gene 
mutation in idiopathic chronic pancreatitis which lands support to the genetic theory 
of aeitopathogenesis of idiopathic chronic pancreatitis.  The present study shows 
phenotypic and genetic similarities   between idiopathic CP in India and in other 
countries.  
Our study reveals that SPINK1 mutation is strongly associated with more 
number of acute episodes in idiopathic recurrent acute pancreatitis and parenchymal 
calcification in chronic pancreatitis. We need to carry out this study in more number 
of patients and replicate results for confirmation. Also it may be useful to do 
functional studies of SPINK1 mutation in cell cultures to understand the 
pathophysiology of disease status more completely.  
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SUMMARY 
 
 
· The prospective study was done to evaluate clinical profile and SPINK1 
genetic mutation in idiopathic recurrent acute and chronic pancreatitis. 
· Total of 50 patients out of whom 17 were recurrent acute pancreatitis and 33 
idiopathic chronic pancreatitis. 
· Most of the patients in both the group were below 30 yrs.  
· Male preponderance was seen in both groups. 
· Majority of patients had BMI > 18.5 kg/m2 in both groups. 
· In idiopathic recurrent acute pancreatitis 41.17% of patients were SPINK1 
mutation positive. 
· 36.36% of patients with idiopathic CP were positive for SPINK1  mutation 
· Patients with SPINK positive had more number of pain episodes compared to 
wild type in RAP groups. 
· In idiopathic chronic pancreatitis pain was predominant symptom. 
· In idiopathic chronic pancreatitis diabetes was seen only in 33.33 %.  
· In idiopathic chronic pancreatitis all patients with SPINK positive mutation 
had showed parenchymal calcification by CT scan. 
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CONCLUSION 
 
 
· This is one of the few studies in South Indian population done to assess 
SPINK 1 mutation and clinical correlates in idiopathic recurrent acute 
pancreatitis and idiopathic chronic pancreatitis.  
· The prevalence of SPINK1 mutation in idiopathic RAP and CP were found to 
be 41.17% and 36.36% respectively. 
· SPINK1 mutation patients in idiopathic RAP group had more number of acute 
pain episodes 
· SPINK1 mutation patients in idiopathic chronic pancreatitis showed 100% 
parenchymal calcification by CT. 
· Clinical profile of idiopathic chronic pancreatitis is different from what has 
been reported previously. 
· Genetic testing and screening may be proposed to have role in diagnosis, 
predection of clinical features and severity in future.   
· More replicative studies need to be done to substantiate the results.   
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PROFORMA
1. Name :
2. Age :
3. Sex :
4. Date of Admission :
5. Presenting Complaint :
6. Past History :
7. Examination : Pulse BP Respiratory System
CVS Abdomen
8. Investigations : CBC Creatinine
FBS Calcium
Lipid Profile Thyroid profile
PTH ANA IG4 levels
9. Serology Test
10. Bile for Micorlithiasis
11. Ultra Sound
12. CT Abdomen
13. EUS/ MRCP
14. Genetic Analysis
COLOUR PLATE
Picture showing PCR amplification of DNA
COLOUR PLATE
Picture showing 2% agarose gel electrophoresis of PCR Product
COLOUR PLATE
Picture showing 12% Polyacrylamide gel electrophoresis of digested RFLP
DNA ISOLATION SAMPLES 31-40
1 2 3 4 5 6 7 8 9 10 11 12 13
WELLS 2 -6 & 8-12 - GENOMIC DNA
RFLP PCR FOR SAMPLES 31-40
1 2 3 4 5 6 7 8 9 10 11 12 13
WELL 7 - LADDER 100bp
WELLS  2-6 & 8-12 - PCR PRODUCT 320bp
300bp 320bp
12 % PAGE FOR SAMPLES 21- 30
12 % PAGE FOR SAMPLES 31- 40
WELL 1 - LADDER - 100 bp
WELL 2 - UNCUT - 320bp
WELLS 3,5,6,7,8,9 & 12   - WILD TYPE - 320bp
WELL 4,10 &11 - HETEROZYGOUS - 320bp+286bp
1 2 3 4   5 6 7 8 9 10 11 12   13
300bp
320bp
320bp +286bp
12 % PAGE FOR SAMPLES 31- 40
320bp
12 % PAGE FOR SAMPLES 41- 50
1 2 3 4 5 6 7 8 9 10 11 12 13
WELL 1 - UNCUT - 320 bp
WELL 2 - LADDER - 100bp
WELL  3 - ‘ + ’ CONTROL MUTANT - 286bp
WELLS 4,9,10 & 12 - WILD TYPE - 320bp
WELL 6,7,8,11 &13 - HETEROZYGOUS - 320bp+286bp
WELL   5 - MUTANT - 286bp
320bp 320bp +286bp
320bp
300bp
 ABSTRACT 
Recurrent acute pancreatitis and chronic pancreatitis are labeled as idiopathic when no 
identifiable factors are found. The identifications of genetic mutations associated with 
pancreatitis have provided opportunities for identifying patients at risk for idiopathic 
pancreatitis.  
Aim:  
To study of clinical profile and prevalence of SPINK 1 mutation in idiopathic 
recurrent acute and chronic pancreatitis. 
Design:  
Prospective observational study of patients with idiopathic recurrent and chronic 
pancreatitis in a tertiary care hospital from November 2010 to 31st October 2011.  
Results: 
Fifty patients were included out which 17 patients were idiopathic recurrent acute 
pancreatitis and 33 were chronic. Out of 17 patients with RAP mean age was 22.29 ± 9.7 
years, duration of illness was 28.23 ± 10.34 months, 82% were male, 94% had BMI > 18.5 
kg/ m2  41.17% had SPINK1 mutation. Out of 33 patients with chronic pancreatitis mean age 
was 31.75 ± 13.07 year, duration of illness was 31.33 ± 19.89 months, mean  fasting sugar 
was 112.57 mg/dl, 67% were male, 93.94% had pain 87.8% had ductal dilatation on CT, 
36.36% were SPINK 1 positive.  
 
 Conclusion: 
SPINK1 mutation patients have more frequent episodes of pancreatitis and 
parenchymal calcification on CT. The clinical profile of idiopathic chronic pancreatitis is 
different from what has been reported in the past. 
Key words:  
Idiopathic Recurrent Acute Pancreatitis; Chronic Pancreatitis SPINK1 mutation  
 
 
 
 
 
 
 
 
 
 
 
